Effects of EGFR Mutations on NSCLC Patients Treated by Ramucirumab plus Docetaxel

The present paper attempted to define the effects of epidermal growth factor receptor (EGFR) mutations on patients with non-small cell lung cancer (NSCLC) treated by ramucirumab plus docetaxel. Of 82 enrolled patients, 48 underwent EGFR mutations, showing relevance sex and smoking history (P<0.05). analysis yielded that EGFR-mutant (EGFR-Mut) group had a higher objective response rate versus EGFR-wild-type (EGFR-Wt) Subsequent treatment, serum VEGF, bFGF, HDGF, CEA, CA153, CYFRA21-1 CA199 levels dropped more significantly in EGFR-Mut Beyond that, exhibited lower ZPS score KPS EGFR-Wt Further, displayed strikingly longer median survival time Ramucirumab docetaxel can safely inhibit tumour angiogenesis regulate markers. NSCLC brain metastasis have better treatment outcomes survival.